Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label rollover study of gantenerumab in Alzheimer's disease
NL-OMON52664Phase 3Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of gantenerumab in Alzheimer's disease (AD), sponsored by Roche. Primary endpoint: Long-term safety and tolerability of gantenerumab. Started Aug 2020; status: active, not recruiting.
02
Drugs
gantenerumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON52664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52664.